Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

1. AGA Clinical Practice Update on Young Adult Onset Colorectal Cancer Diagnosis and Management: Expert Review

are typically chromosomally stable, while roughly half of microsatellite stable CRCs are chromosomally unstable and the other half are microsatellite and chromosome stable (MACS). Banerjea A. Hands R.E. Powar M.P. et al. Microsatellite and chromosomal stable colorectal cancers demonstrate poor immunogenicity and early disease recurrence. Colorectal Dis. 2009; 11 : 601-608 MACS tumors often arise in the distal colon and rectum and are less likely to produce the immune response of many MSI tumors with tumor (...) features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. Mod Pathol. 2012; 25 : 1128-1139 Additionally, tumors are also more likely to be poorly differentiated Jones H.G. Radwan R. Davies M. et al. Clinicopathological characteristics of colorectal cancer presenting under the age of 50. Int J Colorectal Dis. 2015; 30 : 483-489 and are more likely to involve the distal

2020 American Gastroenterological Association Institute

2. Identifying Features of Screening Approaches for People at Increased Risk of Colorectal Cancer

the guidelines when defining individuals at average CRC risk, which typically included those who are above the age of 50 years with no personal or family history of CRC, with no risk factors (e.g., hereditary syndromes such as familial adenomatous polyposis or Lynch syndrome), without a history of abdominal or pelvic radiation due to previous cancer, or a history of inflammatory bowel disease.(4-9) One guideline from 2017 by the US Multi-Society Task Force on Colorectal Cancer recommended that the African (...) of 60 • History of inflammatory bowel disease • Suspected or confirmed hereditary CRC syndrome • Suspected or confirmed history of abdominal or pelvic radiation • Family history and genetic counselling referrals for hereditary syndromes Identifying Features of Screening Approaches for People at Increased Risk for Colorectal Cancer 12 Evidence >> Insight >> Action Evidence source Document characteristics Average CRC risk Increased CRC risk Screening criteria Features of approaches for managing CRC

2020 McMaster Health Forum

3. Multicomponent Interventions to Improve Screening for Breast, Cervical or Colorectal Cancer

Multicomponent Interventions to Improve Screening for Breast, Cervical or Colorectal Cancer Oregon Health Authority : Evidence-based Reports Blog : Health Evidence Review Commission : State of Oregon menu Toggle Main Menu Main Navigation close search Search search Submit You are here: Evidence-based Reports Blog menu Site Navigation Evidence-based Reports Blog Full Width Column 1 Select Ablation for Atrial Fibrillation Acellular Dermal Matrix for Post-Mastectomy Breast Reconstruction Compliance (...) ={ListId}'); return false;} if(pageid == 'audit') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+ '/_layouts/15/Reporting.aspx' +'?Category=Auditing&backtype=item&ID={ItemId}&List={ListId}'); return false;} if(pageid == 'config') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+ '/_layouts/15/expirationconfig.aspx' +'?ID={ItemId}&List={ListId}'); return false;}}, null); 0x0 0x1 ContentType 0x01 898 BlogTopic Multicomponent Interventions to Improve Screening for Breast, Cervical or Colorectal Cancer

2020 Oregon Health Evidence Review Commission

4. Ripretinib (Qinlock) - for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST

Ripretinib (Qinlock) - for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent

2020 Health Canada - Drug and Health Product Register

5. Avapritinib (Ayvakyt) - gastrointestinal stromal tumour (GIST)

of Ayvakyt and why it is authorised in the EU What is Ayvakyt and what is it used for? Ayvakyt is a cancer medicine used to treat gastrointestinal stromal tumour (GIST), a cancer of the stomach and bowel, that cannot be removed by surgery and has spread to other parts of the body. Ayvakyt is used when the cancer cells have a D842V mutation, a change in the gene for the platelet- derived growth factor receptor alpha (PDGFRA). GIST is rare, and Ayvakyt was designated an ‘orphan medicine’ (a medicine used (...) Avapritinib (Ayvakyt) - gastrointestinal stromal tumour (GIST) Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/424166/2020 EMEA/H/C/005208 Ayvakyt (avapritinib) An overview

2020 European Medicines Agency - EPARs

6. Avapritinib (Ayvakyt) for the treatment of gastrointestinal stromal tumours (GIST)

Avapritinib (Ayvakyt) for the treatment of gastrointestinal stromal tumours (GIST) Avapritinib (Ayvakyt®) for the treatment of gastrointestinal stromal tumours (GIST) - Repository of AIHTA GmbH English | Browse - - - Avapritinib (Ayvakyt®) for the treatment of gastrointestinal stromal tumours (GIST) Grössmann, N. (2020): Avapritinib (Ayvakyt®) for the treatment of gastrointestinal stromal tumours (GIST). Oncology Fact Sheet Nr. 16. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert

2020 Austrian Institute of Health Technology Assessment

7. Expert guidance on screening for colorectal and pancreatic cancer in BRCA1 and BRCA2 carriers

Expert guidance on screening for colorectal and pancreatic cancer in BRCA1 and BRCA2 carriers Expert guidance on screening for colorectal and pancreatic cancer in BRCA1 and BRCA2 carriers | American Gastroenterological Association Login here Gastro.org Gastro.org AGA Journals AGA Journals AGA’s peer-reviewed journals offer high-quality research on current advances in GI and hepatology. Access the latest research from Gastroenterology , Clinical Gastroenterology and Hepatology , Cellular (...) options for digestive disease patients. AGA Community AGA Community AGA Community is your hub for connecting with your fellow GI professionals in a private, member-only discussion forum. AGA Job Board AGA Job Board AGA’s official job board, GICareerSearch.com, features new job postings daily. Employers can also post open positions. Menu MENU MENU Doctors using laptop in gabinet, writing documents. Guidelines Evidence-based recommendations to guide your clinical decisions. Male doctor reading medical

2020 American Gastroenterological Association Institute

8. Efficacy of Real-Time Computer-Aided Detection of Colorectal Neoplasia in a Randomized Trial

, Kuwait, Kuwait. 5 Digestive Endoscopy, Nuovo Regina Margherita Hospital, Rome, Italy. 6 Mayo Clinic, Jacksonville, Florida. 7 Kansas City Veterans Affairs Hospital, Kansas City, Missouri. 8 Department of Interdisciplinary Endoscopy, University Hospital Hamburg-Eppendorf, Hamburg, Germany. PMID: 32371116 DOI: Item in Clipboard Full-text links Cite Display options Display options Format Abstract Background & aims: One-fourth of colorectal neoplasias are missed during screening colonoscopies; these can (...) develop into colorectal cancer (CRC). Deep learning systems allow for real-time computer-aided detection (CADe) of polyps with high accuracy. We performed a multicenter, randomized trial to assess the safety and efficacy of a CADe system in detection of colorectal neoplasias during real-time colonoscopy. Methods: We analyzed data from 685 subjects (61.32 ± 10.2 years old; 337 men) undergoing screening colonoscopies for CRC, post-polypectomy surveillance, or workup due to positive results from a fecal

2020 EvidenceUpdates

9. Self-expandable metal stents for obstructing colonic and extracolonic cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2020

389Introduction Colorectal cancer is one of the most common cancers world- wide, particularly in the economically developed world [1]. Large-bowel obstruction caused by advanced colonic cancer occurs in 8%–13% of colonic cancer patients [2–4]. The man- agementof thissevereclinicalconditionhasbeencontroversial [5].Over thelastdecade,manyarticleshavebeenpublishedon the subject of colonic stenting for malignant colonic obstruc- tion, including randomized controlled trials (RCTs) and sys- tematic reviews. Thereby (...) ThisGuidelineisanofficialstatementoftheEuropeanSo- cietyof Gastrointestinal Endoscopy(ESGE). Itis a revision of the previously published 2014 Guideline addressing the role of self-expandable metal stents for obstructing colonic and extracolonic cancer. ABBREVIATIONS ASA American Society for Anesthesiologists CI confidence interval CT computed tomography CTC computed tomography colonoscopy ECM extracolonic malignancy ESGE European Societyof Gastrointestinal Endoscopy GRADE Grading of Recommendations Assessment, De- velopment and Evaluation HR

2020 European Society of Gastrointestinal Endoscopy

10. Localised Colon Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

or tests using other markers (e.g. M2-PK) lack formal comparisons of their performance, and integration with other assays needs to be monitored. Screening for high-risk populations is covered in the ESMO guidelines for hereditary gastrointestinal cancer [11]. DIAGNOSIS Symptoms and signs Colon cancer arises from the mucosa of the bowel, growing both into the lumen and the bowel wall, and/or spreading to adjacent organs. Symptoms are associated with relatively large tumours and/or advanced disease (...) and Colon Cancer Outcome. JAMA Oncol. 2018; 4(3):309-315. 22. Duffy MJ, van Dalen A, Haglund C et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer. 2003; 39: 718–727. 23. Locker GY, Hamilton S, Harris J et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006; 24: 5313–5327. 24. van der Geest LG, Lam-Boer J, Koopman M et al. Nationwide trends in incidence

2020 European Society for Medical Oncology

11. An RCT of Fecal Immunochemical Test Colorectal Cancer Screening in Veterans Without Recent Primary Care

An RCT of Fecal Immunochemical Test Colorectal Cancer Screening in Veterans Without Recent Primary Care An RCT of Fecal Immunochemical Test Colorectal Cancer Screening in Veterans Without Recent Primary Care - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public (...) new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Am J Prev Med Actions . 2020 Jul;59(1):41-48. doi: 10.1016/j.amepre.2020.02.014. An RCT of Fecal Immunochemical Test Colorectal Cancer Screening in Veterans Without Recent Primary Care , , , , , Affiliations Expand Affiliations 1 Corporal

2020 EvidenceUpdates

12. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial

Actions Aged, 80 and over Actions Double-Blind Method Actions Female Actions Follow-Up Studies Actions Gastrointestinal Neoplasms / drug therapy* Actions Gastrointestinal Neoplasms / pathology Actions Gastrointestinal Stromal Tumors / drug therapy* Actions Gastrointestinal Stromal Tumors / pathology Actions Humans Actions Male Actions Middle Aged Actions Phenylurea Compounds / therapeutic use* Actions Prognosis Actions Pyridines / therapeutic use* Actions Survival Rate Actions Young Adult Actions (...) Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily

2020 EvidenceUpdates

13. Comparative Evaluation of Participation and Diagnostic Yield of Colonoscopy vs Fecal Immunochemical Test vs Risk-Adapted Screening in Colorectal Cancer Screening: Interim Analysis of a Multicenter Randomized Controlled Trial (TARGET-C)

of Sciences/Zhejiang Cancer Hospital. 4 Department of Cancer Prevention, Hunan Cancer Hospital, Changsha, China. 5 Office of Cancer Prevention and Treatment, Xuzhou Cancer Hospital, Xuzhou, China. 6 Department of Cancer Prevention, Anhui Provincial Cancer Hospital, Hefei, China. 7 Department of Colorectal Surgery, Tumor Hospital of Yunnan Province/Third Affiliated Hospital of Kunming Medical University, Kunming, China. 8 Department of Medical Oncology, Institute of Cancer and Basic Medicine (ICBM (...) , China. 13 Department of NCD Prevention and Heath Education, Hefei Center for Disease Control and Prevention, Hefei, China. 14 Department of Cancer Prevention, Tumor Hospital of Yunnan Province/Third Affiliated Hospital of Kunming Medical University, Kunming, China. 15 Henan Office for Cancer Control and Research, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China. 16 Department of Epidemiology and Biostatistics, and the Ministry of Education Key Lab

2020 EvidenceUpdates

14. Short-term Outcomes of Single-port Versus Multiport Laparoscopic Surgery for Colon Cancer: The SIMPLE Multicenter Randomized Clinical Trial

2017 at 7 sites in Korea. A total of 388 adults (aged 19-85 yrs) with clinical stage I, II, or III adenocarcinoma of the ascending or sigmoid colon were enrolled and randomized. The primary endpoint was 30-day postoperative complication rates. Secondary endpoints were the number of harvested lymph nodes, length of the resection margin, postoperative pain, and time to functional recovery (bowel movement and diet). Patients were followed for 30 days after surgery. Results: Among 388 patients, 359 (...) Short-term Outcomes of Single-port Versus Multiport Laparoscopic Surgery for Colon Cancer: The SIMPLE Multicenter Randomized Clinical Trial Short-term Outcomes of Single-port Versus Multiport Laparoscopic Surgery for Colon Cancer: The SIMPLE Multicenter Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable

2020 EvidenceUpdates

15. Ripretinib (Qinlock) - To treat advanced gastrointestinal-stromal tumors

Ripretinib (Qinlock) - To treat advanced gastrointestinal-stromal tumors Drug Approval Package: QINLOCK U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: QINLOCK Company: Deciphera Pharmaceuticals, LLC Application Number: 213973 Approval Date: 05/15/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF

2020 FDA - Drug Approval Package

16. Is 45 really the new 50 in colorectal cancer screening?

Is 45 really the new 50 in colorectal cancer screening? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca June 29, 2020 (...) Is 45 really the new 50 in colorectal cancer screening? Clinical Question: Should we lower the age that average risk patients commence colorectal cancer screening from 50 to 45? Bottom Line: In developed countries, the incidence of colorectal cancer in persons under 50 years old has increased by 20-30% in the last 20 years. However, the absolute risk increase is only 1-4 per 100,000 persons. Screening average risk patients under age 50 should not be encouraged at this time. Evidence: • Population

2020 Tools for Practice

17. A systematic mixed studies review of health behaviour change interventions in colorectal cancer survivors

A systematic mixed studies review of health behaviour change interventions in colorectal cancer survivors A systematic mixed studies review of health behaviour change interventions in colorectal cancer survivors - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National (...) RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Review J Adv Nurs Actions . 2020 Apr 13. doi: 10.1111/jan.14389. Online ahead of print. A systematic mixed studies review of health behaviour change interventions in colorectal cancer survivors , , , Affiliations Expand Affiliation 1 School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada. PMID: 32281687 DOI: Item in Clipboard Review A systematic mixed studies review

2020 EvidenceUpdates

18. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Full Text available with Trip Pro

Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lynch syndrome is associated with an increased risk of colorectal cancer and with a broader spectrum of cancers, especially endometrial cancer. In 2011, our group reported long-term cancer outcomes (mean follow-up 55·7 months [SD 31·4]) for participants with Lynch syndrome enrolled (...) outcomes were monitored for at least 10 years from recruitment with English, Finnish, and Welsh participants being monitored for up to 20 years. The primary endpoint was development of colorectal cancer. Analysis was by intention to treat and per protocol. The trial is registered with the ISRCTN registry, number ISRCTN59521990.Between January, 1999, and March, 2005, 937 eligible patients with Lynch syndrome, mean age 45 years, commenced treatment, of whom 861 agreed to be randomly assigned

2020 Lancet

19. Simultaneous Versus Delayed Resection for Initially Resectable Synchronous Colorectal Cancer Liver Metastases: A Prospective, Open-label, Randomized, Controlled Trial

of Digestive, Endocrine, Oncologic and Liver Transplant Surgery, University Hospital, François Rabelais University, Tours, France. 10 Department of Hepatobiliary, Oncologic and Transplant Surgery, AP-HP, Paul Brousse Hospital, Paris-Sud University, Villejuif, France. PMID: 32209911 DOI: Item in Clipboard Full-text links Cite Abstract Objective: To answer whether synchronous colorectal cancer liver metastases (SLM) should be resected simultaneously with primary cancer or should be delayed. Summary (...) background data: Numerous studies have compared both strategies. All were retrospective and conclusions were contradictory. Methods: Adults with colorectal cancer and resectable SLM were randomly assigned to either simultaneous or delayed resection of the metastases. The primary outcome was the rate of major complications within 60 days following surgery. Secondary outcomes included overall and disease-free survival. Results: A total of 105 patients were recruited. Eighty-five patients (39 and 46

2020 EvidenceUpdates

20. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, rand Full Text available with Trip Pro

: TRIBE2 was an open-label, phase 3, randomised study of patients aged 18-75 years with an Eastern Cooperative Oncology Group (ECOG) performance status of 2, with unresectable, previously untreated metastatic colorectal cancer, recruited from 58 Italian oncology units. Patients were stratified according to centre, ECOG performance status, primary tumour location, and previous adjuvant chemotherapy. A randomisation system incorporating a minimisation algorithm was used to randomly assign patients (1:1 (...) , and one sepsis). Interpretation: Upfront FOLFOXIRI plus bevacizumab followed by the reintroduction of the same regimen after disease progression seems to be a preferable therapeutic strategy to sequential administration of chemotherapy doublets, in combination with bevacizumab, for patients with metastatic colorectal cancer selected according to the study criteria. Funding: The GONO Cooperative Group, the ARCO Foundation, and F Hoffmann-La Roche. Copyright © 2020 Elsevier Ltd. All rights reserved

2020 EvidenceUpdates